Scientific deep-dive

Semaglutide and Kidneys: Pooled SELECT, FLOW and SOUL Results

A prespecified pooled analysis of SELECT, FLOW and SOUL (30,787 people) found fewer events on a composite of kidney outcomes and cardiovascular death (HR 0.84) and on a kidney-only version (HR 0.80). What it counts, how much FLOW drives it, and what labels still limit.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
7 min read·11 citations

Semaglutide reduced serious kidney events when three large trials were combined. In a prespecified participant-level pooled analysis of SELECT, FLOW and SOUL (N=30,787), 973 first events of the primary kidney composite occurred on semaglutide and 1,134 on placebo (HR 0.84; 95% CI 0.77 to 0.91).[1] That composite counts cardiovascular death, and the narrower kidney-only version gave HR 0.80 (95% CI 0.69 to 0.92).[1] Novo Nordisk, which makes semaglutide, funded the analysis.[1] It does not change what the labels say: among US semaglutide products, only injected Ozempic has a kidney indication, in adults with type 2 diabetes and chronic kidney disease.[9]

Three different trials, one question

The appeal of pooling is breadth. Our FLOW overview covers people with type 2 diabetes and established kidney disease, the population in which the drug earned its kidney indication. SELECT enrolled people with overweight or obesity and cardiovascular disease, without diabetes.[3] SOUL enrolled people aged 50 or older with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease or both.[5] Those groups differ in nearly everything except the molecule, and each trial used its own dose or route.

The three trials in the pooled analysis, with each trial’s own kidney result
MeasureSELECTFLOWSOUL
PopulationOverweight or obesity with cardiovascular disease, no diabetesType 2 diabetes and chronic kidney diseaseType 2 diabetes with cardiovascular disease, kidney disease or both
Semaglutide2.4 mg weekly, injected1.0 mg weekly, injectedUp to 14 mg daily, oral
Randomized17,6043,5339,650
Own kidney compositeHR 0.78 (0.63 to 0.96)HR 0.76 (0.66 to 0.88)HR 0.91 (0.80 to 1.05)
Composite includesMacroalbuminuria, no cardiovascular deathCardiovascular deathCardiovascular death
Statistically significant?Yes, P=0.02Yes, P=0.0003No, P=0.19

The table draws on each trial’s kidney report: SELECT,[3] FLOW[2] and SOUL.[4] The SELECT arm sizes (8,803 and 8,801) add to 17,604, and the three totals add to the pooled 30,787.[1][2][3][5] Mean follow-up across the pooled trials was 39.5 to 47.5 months, and FLOW was stopped early after a prespecified interim analysis recommended it, at a median of 3.4 years.[1][2]

What the headline number measures

The pooled primary outcome was time to the first of four events: a persistent eGFR drop of 50% or more, kidney failure (persistent eGFR below 15 or kidney replacement therapy), kidney-related death or cardiovascular-related death.[1] Cardiovascular death matters a great deal in that list. The SOUL investigators wrote that their similar composite “was dominated by CV death” and that the trial was not powered for major kidney outcomes.[4] In SOUL, the five-point composite had 403 and 435 events, while the four-point version without cardiovascular death had only 112 and 129.[4]

So the more telling line in the pooled paper is the secondary composite, which drops cardiovascular death: 347 events on semaglutide and 416 on placebo (HR 0.80; 95% CI 0.69 to 0.92).[1] That is the closest thing here to a pure kidney result, and it still favors the drug.

In absolute terms

The abstract gives events and a hazard ratio but no percentages. Using the arm sizes from the individual trial reports (15,395 on semaglutide and 15,392 on placebo), crude event proportions work out to about 6.3% versus 7.4% for the primary composite and about 2.3% versus 2.7% for the kidney-only composite.[1][2][3][5] That is our arithmetic. It ignores differing follow-up and is not a figure from the paper, but it shows the scale: a difference of roughly one percentage point over several years, in a high-risk group, most of whom were not enrolled because of kidney disease.

FLOW carries more weight than its size suggests

FLOW contributed 11% of the participants but, going by its own near-identical composite (331 and 410 first events), about 35% of the events in the pooled primary outcome.[1][2] That is expected, because people with established kidney disease have far more kidney events. It also suggests the pooled estimate draws heavily on the group already known to benefit, so it should not be read as three equal votes. SOUL, by itself, did not show a statistically significant reduction in its composite, and its participants had mostly preserved kidney function, with a mean eGFR of 73.8 mL/min/1.73 m².[4]

The authors say benefit held “regardless of baseline characteristics within the cardio-kidney-metabolic spectrum” and flag differences among the trials in baseline characteristics, dose and route.[1] The abstract does not print trial-by-trial or subgroup hazard ratios, so we do not report any here, and it does not support ranking the oral and injected forms against each other. The trials were not designed for that comparison, and the numerically smaller SOUL result arrives from a different population at lower kidney risk.

Slower eGFR decline shows up in all three

Each trial reported slower loss of kidney function, though on different scales that should not be lined up as if they measured one thing. FLOW’s mean annual eGFR slope was less steep by 1.16 mL/min/1.73 m² per year.[2] SOUL’s mean annual decline was -1.67 versus -2.06, a difference of 0.40.[4] SELECT reported a benefit of 0.75 at 104 weeks overall and 2.19 in those starting below an eGFR of 60.[3] For more on how the FLOW slope varied by kidney severity, see our FLOW subgroup breakdown.

How far the result extends

The inclusion criteria set the limit. Every pooled participant had chronic kidney disease or atherosclerotic cardiovascular disease.[1] Someone with obesity alone, no cardiovascular disease and healthy kidneys was not in these trials, so the results do not speak directly to that person. About 57% of the pooled participants came from SELECT, which is why the analysis has something to say about people without diabetes at all, though only those with cardiovascular disease.[1][3]

The results also fit a wider pattern. A meta-analysis of 11 GLP-1 trials with 85,373 participants, published before SOUL and reporting no funding, found a composite kidney outcome HR of 0.81 (95% CI 0.72 to 0.92) with SELECT included.[6] It overlaps with this analysis, at least through SELECT, so the two are not fully independent confirmation of each other.[6]

On mechanism

The pooled authors suggest the benefit “might not be explained only” by glucose or weight effects.[1] That is a hypothesis. The Ozempic label states flatly: “The mechanism of kidney-related risk reduction has not been established.”[9]

Safety

The pooled authors describe safety as overall similar between groups, with serious adverse events numerically lower on semaglutide.[1] A FLOW safety analysis by baseline kidney function points the same way, with serious events at 56.4% versus 60.4% in people with an eGFR under 30, in a descriptive assessment.[7] That does not mean tolerability was equal. Stopping because of gastrointestinal side effects was more common on semaglutide in FLOW (4.5% versus 1.1%), and the broader GLP-1 meta-analysis found more discontinuation for adverse events (RR 1.51; 95% CI 1.18 to 1.94).[6][7]

The labels still carry a warning about acute kidney injury, with postmarketing reports that in some cases required hemodialysis, mostly tied to dehydration from nausea, vomiting or diarrhea.[9][11] A kidney benefit over years and a short-term dehydration risk can both be true, and our article on Ozempic and acute kidney injury covers the practical side. For people who reach dialysis, a separate post hoc analysis of four trials followed 165 participants who stayed on treatment after starting dialysis. Serious events occurred in 45% on semaglutide and 57% on placebo; the authors said it “appears safe” and that efficacy still needs testing.[8]

What each label says

  • Ozempic injection (June 2026 label): indicated “to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death” in adults with type 2 diabetes and chronic kidney disease.[9] FLOW excluded people with polycystic kidney disease, glomerulonephritis and other autoimmune kidney diseases, and congenital urinary tract malformations.[9]
  • Rybelsus and Ozempic tablets (January 2026 label): indicated for glycemic control and to reduce major cardiovascular events in adults with type 2 diabetes at high risk. There is no kidney indication.[10]
  • Wegovy (June 2026 label): carries the acute kidney injury warning. Its indications do not include kidney protection.[11]

What to raise with your prescriber

  • Do I fit one of these trial populations? Ask about your eGFR and urine albumin-to-creatinine ratio (UACR), plus any cardiovascular disease and diabetes history.[1][2]
  • If I have type 2 diabetes and kidney disease, is the labeled 1 mg injected dose the one being used for kidney protection?[9]
  • If my kidney disease has a specific cause such as glomerulonephritis or polycystic disease, do these results apply? FLOW excluded those conditions.[9]
  • What should I do about fluids and kidney labs if I develop persistent vomiting or diarrhea?[9]

Our reviews

Providers that offer semaglutide

Telehealth providers we’ve reviewed. Each opens our full, independent review.

We may earn a commission from featured partners. Learn more

See the full ranking →

Frequently Asked Questions

The evidence is supportive but limited to specific groups. In SELECT, people with overweight or obesity and cardiovascular disease, without diabetes, had a lower rate of a kidney composite on semaglutide 2.4 mg (1.8% vs 2.2%; HR 0.78). That trial’s result fed the pooled analysis. Wegovy's label does not include a kidney indication.
This has not been directly tested. SOUL, using oral semaglutide up to 14 mg daily, did not show a statistically significant reduction in its kidney composite (HR 0.91; 95% CI 0.80 to 1.05), though eGFR decline was slower. FLOW used injected 1.0 mg in people at much higher kidney risk, so the two results cannot be compared head to head.
The pooled analysis reported composites, which combine kidney failure with other events. The kidney-only composite fell with an HR of 0.80 (347 vs 416 events). The abstract does not give a separate figure for kidney failure alone, and absolute differences were small: about 2.3% vs 2.7% by crude calculation.
These trials did not test that. Everyone in the pooled analysis had chronic kidney disease or atherosclerotic cardiovascular disease. Only the Ozempic injection has a kidney indication, in adults with type 2 diabetes and chronic kidney disease. Ask your prescriber whether your own risk profile matches the people studied.

References

  1. 1.Mann JFE, Badve SV, Baeres FMM, Belmar N, Brown-Frandsen K, Buse JB, et al. Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis. Lancet Diabetes Endocrinol. 2026. PMID: 42567173.
  2. 2.Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024. PMID: 38785209.
  3. 3.Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024. PMID: 38796653.
  4. 4.Mann JFE, Marx N, Deanfield JE, Emerson SS, Inzucchi SE, McGuire DK, et al. Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care. 2026. PMID: 41380027.
  5. 5.McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025. PMID: 40162642.
  6. 6.Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025. PMID: 39608381.
  7. 7.Tuttle KR, Andersen MR, Arici M, Arslan EG, Bellary S, Idorn T, et al. Safety outcomes of semaglutide by chronic kidney disease severity in the FLOW trial. Kidney Int. 2026. PMID: 42901325.
  8. 8.Klein KR, Menacher A, Buse JB, Mann JFE, Tuttle KR, Kvist K, Andersen MR, Mayrdorfer M, Lingvay I. Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis. Diabetes Care. 2026. PMID: 41893299.
  9. 9.Novo Nordisk. OZEMPIC (semaglutide) injection, prescribing information, June 2026 version. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  10. 10.Novo Nordisk. RYBELSUS and OZEMPIC (semaglutide) tablets, prescribing information, January 2026 version. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  11. 11.Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information, June 2026 version. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

SMART Trial: Semaglutide 2.4 mg in Kidney Disease Without Diabetes

Semaglutide 2.4 mg cut urine albumin by 52.1% vs placebo at 24 weeks in 101 adults with chronic kidney disease, excess weight, and no diabetes. Here is what SMART shows, why it is not proof of protection from kidney failure, and how it fits with FLOW and SELECT.

8 min read

FLOW Trial: Semaglutide Kidney Subgroup Detail (2026)

A deep dive into the FLOW trial secondary analyses: eGFR slope, cardiovascular and all-cause death, heart failure, and benefit across CKD severity, SGLT2i, and MRA subgroups.

13 min read

FLOW Trial Update: GLP-1 for CKD Stage 3-4 — The Evidence

Semaglutide reduced major kidney events by 24% in FLOW. We review the eGFR slope, the practical CKD prescribing protocol, the dialysis-imminent patient pathway, and how SURPASS-MULTI shapes tirzepatide's renal positioning.

12 min read

GLP-1 with Kidney Disease (CKD): The Patient Action Plan

If you have CKD and your clinician is considering a GLP-1, here is what changed: FLOW trial Perkovic 2024 NEJM 24% kidney + CV event reduction, AWARD-7 dulaglutide in moderate-severe CKD, no renal dose adjustment for most GLP-1s, sick-day rules with SGLT2 + ACE-I.

14 min read

Retatrutide and kidney protection: Phase 2 post-hoc evidence and TRANSCEND-CKD

Retatrutide is investigational and not FDA-approved. Heerspink 2025 Kidney Int Rep post-hoc Phase 2: 12 mg cut UACR -37% at 36 wk in T2D; 8/12 mg raised eGFR +5.3/+8.5 mL/min/1.73 m2 in obesity at 48 wk. TRANSCEND-CKD Phase 2b (n=146) results not yet published.

19 min read

FLOW: How Semaglutide Became the First GLP-1 Approved for Diabetic Kidney Disease

In the FLOW trial of 3,533 adults with type 2 diabetes and chronic kidney disease, semaglutide 1.0 mg cut major kidney and cardiovascular events by 24% and was stopped early for benefit. The FDA approved Ozempic for kidney protection on January 28, 2025, a first for a GLP-1.

13 min read

Where to get semaglutide (Ozempic / Wegovy) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

From $129/mo

starting dose

Get started →
8.3

Found

Medication-included compounded GLP-1 on 28-day cash plans, plus insurance help for brand-name GLP-1s

Read full review →

From $169/mo

12-month plan rate

Get started →
8.1

Oak

Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up

Read full review →

From $200/mo

starting dose

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →